ABATACEPT VERSUS TOCILIZUMAB BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TARGETED TREATMENT INADEQUATE RESPONDER PATIENTS: A RANDOMIZED, OPENLABELED, SUPERIORITY TRIAL. -SUNSTAR-

Korábbi kezelés

• counter-indication for one or other of the two drugs under study
• Patient receiving a cortisteroid therapy over 15mg/day prednison equivalent for more than 4 weeks
• Prior treatment by tocilizumab, sarilumab or abatacept
• Prior treatments accepted are TNF alpha inhibitor, rituximab and jak inhibitors

Más betegség

• failure to a first or second line of targeted treatment

Egyéb

• breastfeeding woman

• age >18 years
• RA according to the ACR/EULAR 2010 criteria
• inadequate response to a administered first-line or second line of targeted treatment defined as moderate to high disease activity (DAS28- ESR>3.2 and CDAI>10) after at least 3 months of treatment
• beneficiary of the French National Health Insurance Fund
• signed informed consent form
• for women of childbearing age: effective contraception during treatment period with engagement to continue such contraception for 14 weeks after last administration